Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

671.18
+9.191.39%
Number of Gainers:93
Number of Losers:52
Number of Flat:8
PE:- -
High:673.52
Open:662.15
Low:661.43
Close:662.00
Volume:287.29M
Turnover:7.82B
Market Cap:464.24B
Float Cap:356.88B

Loading ...

U.S. Stocks on the MOVE-Boeing, Robinhood, Lumentum

Reuters
·
Sep 30

Robinhood price target raised to $140 from $130 at KeyBanc

TIPRANKS
·
Sep 30

UiPath Expands Snowflake Partnership with Two-Way Integration for Governed Data and Automation

Reuters
·
Sep 30

CBOE Global Markets, - Co and Robinhood to Offer KPI Binary Options with no Fees Through End of 2026

THOMSON REUTERS
·
Sep 30

CBOE and Robinhood Announce Planned Launch of New KPI Contracts, Further Expanding Prediction Market Offerings

THOMSON REUTERS
·
Sep 30

KeyBanc Adjusts Price Target on Robinhood Markets to $140 From $130, Keeps Overweight Rating

MT Newswires Live
·
Sep 30

Robinhood up 3% in pre-market after announcing extended trading, AI agents

TIPRANKS
·
Sep 30

Candel Therapeutics Reports Phase 3 Prostate Cancer Biomarker Data Showing Sustained Immune Remodeling After Aglatimagene Treatment

Reuters
·
Sep 30

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at Astro 2026

THOMSON REUTERS
·
Sep 30

【US Pre-Market】Boeing Gains Nearly 3%, Moderna Slumps Pre-Market as Market Focuses on PCE and Micron Earnings

TradingKey
·
Sep 30

Robinhood Agents Adds Narravance's Viral Stocks Detector

MT Newswires Live
·
Sep 30

Jade Biosciences advances JADE301 toward Phase 1 trial

TIPRANKS
·
Sep 30

Jade Biosciences announces preclinical data of JADE301

TIPRANKS
·
Sep 30

Zeta Global added to Analyst Conviction List at William Blair

TIPRANKS
·
Sep 30

Jade Biosciences to Start Phase 1 Trial of Dermatomyositis Drug Candidate Jade301 in Q4 2026

Reuters
·
Sep 30

Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback

MT Newswires Live
·
Sep 30

Jade Biosciences Announces Preclinical Data Characterizing Jade301, a Potentially Best-in-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody in Development for Dermatomyositis, at Eadv 2026

THOMSON REUTERS
·
Sep 30

Jade Biosciences, - Jade301 Shows About 25-Day Half-Life and Predictable Muscle Distribution in Primates

THOMSON REUTERS
·
Sep 30

Jade Biosciences, - Jade301 Demonstrates High-Affinity, Selective Ifn-Β Binding and Greater Potency than Dazukibart

THOMSON REUTERS
·
Sep 30

Jade Biosciences, - Phase 1 Trial for Jade301 to Begin in Q4 2026; Interim Data in H2 2027

THOMSON REUTERS
·
Sep 30